Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2480${count})

  • Parkinson’s Disease Therapeutics Pipeline Program, 2025
    Neuro-steroid Mediated Control of Sleep Co-morbidities in Parkinson's Disease

    Study Rationale: Sleep disorders affect a large proportion of people with Parkinson’s disease (PD) and are often refractory to standard medications. Excessive daytime sleepiness (EDS), which is...

  • Parkinson’s Disease Therapeutics Pipeline Program, 2025
    CT600 as a Neuroprotective Peptide Therapeutic for Parkinson’s Disease

    Study Rationale: Excess CDK5 protein kinase activity in the brain caused by the binding of CDK5 with another protein called P25 has been connected to Parkinson's disease. The CDK5-P25 interaction can...

  • Research Grant, 2025
    Analysis of a Potential Alpha-synuclein PET Tracer (18F-FD4) in HC, PD and MSA

    Study Rationale: 18F-FD4 is a new imaging agent that has the potential to image alpha-synuclein in the living human brain with Positron Emission Tomography (PET). Given alpha-synuclein’s central role...

  • Research Grant, 2025
    Scamps: Endosomal Membrane Proteins that Control Alpha-synuclein Traffic

    Study Rationale: Parkinson’s Disease progresses with the death of nerve cells in the brain. Some forms of the disease run in families due to mutations in important genes. One of these genes is called...

  • MRI Biomarkers Program, 2025
    Validate Diffusion MRI Biomarkers of Early PD: A Multi-cohort Study of Free-water and CDM Measure

    Study Rationale: Parkinson’s disease and related synucleinopathies, such as Dementia with Lewy Bodies, are challenging to diagnose at their earliest stages due to subtle initial symptoms. Our research...

  • Parkinson’s Disease Therapeutics Pipeline Program, 2025
    Neuroprotective Therapy for PD Using Stabilizers of the LRRK2:14-3-3 Interaction, Supplement

    Study Rationale: Our previous work shows that regulation of the phosphorylation of the Parkinson’s disease protein ‘leucine-rich repeat kinase 2’ (LRRK2) is a key mechanism controlling LRRK2...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.